Convalescent plasma for COVID-19: A reasonable option for the pandemic based on both scientific and practical point of views

https://doi.org/10.19106/JMedSciSI005203202011

Mardiah Suci Hardianti(1*), Syahru Agung Setiawan(2), David Dwi Putera(3), Teguh Triyono(4), Jarir At Thobari(5), Johan Kurnianda(6)

(1) Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta,
(2) Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta,
(3) Siloam Hospitals Labuan Bajo, Nusa Tenggara Timur,
(4) Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta,
(5) Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(6) Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta,
(*) Corresponding Author

Abstract


Convalescent plasma treatment has become a promising adjunctive option to treat COVID-19. Several case reports consistently supported the feasibility of this approach by showing the safety and improvements of clinical and laboratory aspects from the treated patients. However, more clinical trials are still required to establish the definitive statement about its potential effectiveness. We review the scientific basis for the application of convalescent plasma in COVID-19 to understand its potentials better. We also cover the potential risks and benefits for this treatment in order to be more selective and careful when preparing and deciding to apply this approach. Lastly, we summarize any important points to monitor after the administration of this treatment to prioritize safety and measure the effectiveness of the treatment.


Keywords


convalescent plasma; COVID-19; treatment monitoring; effectiveness; clinical trail;

Full Text:

PDF


References

  1. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016; 14(2):152–157. https://doi.org/10.2450/2015.0131-15
  2. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) iInfection. N Engl J Med 2007; 357(14):1450–1. https://doi.org/10.1056/NEJMc070359
  3. Hung IFN, To KKW, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. Convalescent plasma treatment rReduced mMortality in pPatients wWith sSevere pPandemic iInfluenza A (H1N1) 2009 vVirus iInfection. Clin Infect Dis 2011; 52(4):447–56. https://doi.org/10.1093/cid/ciq106
  4. Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, Uyeki TM, et al. Administration of brincidofovir and convalescent plasma in a patient with ebola virus disease. Clin Infect Dis 2015; 61(6):969–73. https://doi.org/10.1093/cid/civ395
  5. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Eebola virus disease in the United States. Clin Infect Dis 2015; 61(4):496–502. https://doi.org/10.1093/cid/civ334
  6. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of cConvalescent pPlasma for Ebola vVirus dDisease in Guinea. N Engl J Med 2016; 374(1):33–42. https://doi.org/10.1056/NEJMoa1511812
  7. Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4):1545–8. https://doi.org/10.1172/JCI138003
  8. Murira A &, Lamarre A. Type-i interferon responses: from friend to foe in the battle against chronic viral infection. Front Immunol 2016; 19:7. https://doi.org/10.3389/fimmu.2016.00609
  9. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J Aallergy Immunol 2020; 38(1):1–9. https://doi.org/10.12932/AP-200220-0772
  10. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol 2020; https://doi.org/10.1038/s41577-020-0320-7
  11. Tay MZ, Wiehe K, Pollara J. Antibody-dependent cellular phagocytosis in antiviral immune responses. Front Immunol 2019; 28:10. https://doi.org/10.3389/fimmu.2019.00332
  12. Liu W, Fontanet A, Zhang P, Zhan L, Xin Z, Baril L, et al. Two year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis 2006; 193(6):792–5. https://doi.org/10.1086/500469
  13. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798):270–3. http://doi.org/10.1038/s41586-020-2012-7
  14. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020; 27(5):1451–4. https://doi.org/10.1038/s41418-020-0530-3
  15. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, et al. Transfusion-related acute lung injury in the critically Ill. Am J Respir Crit Care Med 2007; 176(9):886–91. https://doi.org/10.1164/rccm.200702-271OC
  16. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 2020; 22(2):72–3. https://doi.org/10.1016/j.micinf.2020.02.006
  17. Ko J-H, Seok H, Cho SY, Eun Ha Y, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018; 23(7):617–22. https://doi.org/10.3851/IMP3243
  18. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-Analysis: convalescent blood products for Sspanish influenza pneumonia: a future Hh5Nn1 treatment? Ann Intern Med 2006; 145(8):599. https://doi.org/10.7326/0003-4819-145-8-200610170-00139
  19. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Gallagher T, editor. J Virol 2019; 94(5):e02015-19. https://doi.org/10.1128/JVI.02015-19
  20. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVIDcovid-19 with convalescent plasma. JAMA 2020; 323(16):1582-9. https://doi.org/10.1001/jama.2020.4783
  21. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci 2020; 202004168. https://doi.org/10.1073/pnas.2004168117
  22. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVIDcovid-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020; 35(14):e149. https://doi.org/10.3346/jkms.2020.35.e149
  23. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol 2020 Apr 15. https://doi.org/10.1002/jmv.25882
  24. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically IiIIll patients with severe acute respiratory syndrome coronavirus-2 SARS-COV-2 infection. Chest 2020; S0012-3692(20)30571-7. https://doi.org/10.1016/j.chest.2020.03.039
  25. Pei S, Yuan X, Zhang ZZ, Yao RR, Xie Y, Shen MM, et al. Convalescent p Plasma to t Treat COVID-19: Chinese Strategy and Experiences. Med Rxiv 2020; https://doi.org/10.1101/2020.04.07.20056440
  26. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; m1256. https://doi.org/10.1136/bmj.m1256
  27. Tiberghien P, de Lambalerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sang. 2020. https://doi.org/10.1111/vox.12926
  28. Choe PG, Perera RAPM, Park WB, Song K-H, Bang JH, Kim ES, et al. MERS-CoV Antibody rResponses 1 yYear after sSymptom oOnset, South Korea, 2015. Emerg Infect Dis 2017; 23(7):1079–84. https://doi.org/10.3201/eid2307.170310
  29. Lu C-L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science (80-) 2016; 352(6288):1001–4. https://doi.org/10.1126/science.aaf1279
  30. Zhang L, Zhang F, Yu W, He T, Yu J, Yi CE, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol 2006; 78(1):1–8. https://doi.org/10.1002/jmv.20499
  31. Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S, et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med 2017; 9(412):eaam5752. https://doi.org/10.1126/scitranslmed.aam5752
  32. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3
  33. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507–13. https://doi.org/10.1016/S0140-6736(20)30211-7
  34. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20(4):425–34. https://doi.org/10.1016/S1473-3099(20)30086-4
  35. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2019; 27:201160. https://doi.org/10.1148/radiol.2020201160



DOI: https://doi.org/10.19106/JMedSciSI005203202011

Article Metrics

Abstract views : 6716 | views : 7313


Bookmark and Share


Copyright (c) 2020 Mardiah Suci Hardianti, Syahru Agung Setiawan, David Dwi Putera, Teguh Triyono, Jarir At Thobari, Johan Kurnianda

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.